Hemicrania Continua Responds to Cyclooxygenase-2 Inhibitors
Article first published online: 15 AUG 2002
Headache: The Journal of Head and Face Pain
Volume 42, Issue 6, pages 530–531, June 2002
How to Cite
Peres, M. F.P. and Silberstein, S. D. (2002), Hemicrania Continua Responds to Cyclooxygenase-2 Inhibitors. Headache: The Journal of Head and Face Pain, 42: 530–531. doi: 10.1046/j.1526-4610.2002.02131.x
- Issue published online: 15 AUG 2002
- Article first published online: 15 AUG 2002
- Accepted for publication March 11, 2002.
- hemicrania continua;
- COX-2 inhibitors
Background.—Hemicrania continua is a primary headache disorder defined by its absolute responsiveness to indomethacin. We report the treatment response to two cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, in a series of patients with hemicrania continua.
Methods.—Fourteen patients were treated, 9 with rofecoxib and 5 with celecoxib.
Results.—Three patients in each group had a complete response to treatment.
Conclusion.—The cyclooxygenase-2 inhibitors may represent an alternative to indomethacin in the treatment of hemicrania continua. Their mechanism of action for this potential indication is unknown.